In Vivo Efficacy of Cefiderocol against Ceftolozane/Tazobactam- and Ceftazidime/Avibactam-Resistant Pseudomonas Aeruginosa Carrying the AmpC E219K Substitution

UDC.coleccionInvestigación
UDC.departamentoMedicina
UDC.grupoInvInvestigación en Microbiología (INIBIC)
UDC.institutoCentroINIBIC - Instituto de Investigacións Biomédicas de A Coruña
UDC.issue10
UDC.journalTitleAntimicrobial Agents and Chemotherapy
UDC.startPagee0072426
UDC.volume70
dc.contributor.authorRodríguez-Coello, Arianna
dc.contributor.authorOuteda-García, Michelle
dc.contributor.authorGarcía-Pose, Andrea
dc.contributor.authorGonzález-Pinto, Lucía
dc.contributor.authorBáez-Barroso, Gabriela Alejandra
dc.contributor.authorGuijarro-Sánchez, Paula
dc.contributor.authorMuras, Andrea
dc.contributor.authorTaltavull, Biel
dc.contributor.authorFraile-Ribot, Pablo Arturo
dc.contributor.authorAlonso-García, Isaac
dc.contributor.authorOliver, Antonio
dc.contributor.authorVázquez-Ucha, Juan Carlos
dc.contributor.authorArca-Suárez, Jorge
dc.contributor.authorBou, Germán
dc.contributor.authorBeceiro Casas, Alejandro
dc.date.accessioned2026-10-19T07:04:55Z
dc.date.available2026-10-19T07:04:55Z
dc.date.issued2026-09-16
dc.descriptionBrief report
dc.description.abstract[Abstract] Chromosomal AmpC variants selected during ceftolozane/tazobactam or ceftazidime/avibactam therapy may affect cefiderocol activity. We evaluated the impact of the E219K substitution on cefiderocol efficacy using isogenic Pseudomonas aeruginosa pairs in a murine bacteremia model. Cefiderocol achieved greater bacterial reductions in parental isolates than in E219K derivatives, despite susceptible MICs. Cefiderocol failed to achieve stasis against a cefiderocol-resistant isolate. E219K impaired cefiderocol efficacy in vivo, supporting close monitoring of cefiderocol activity against isolates carrying this variant.
dc.description.sponsorshipThis research was supported by projects PI23/00851 awarded to A.B., PI24/00920 awarded to G.B., and PI22/01212 and PI25/00116 awarded to J.A.-S. that were all funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. The research was also supported by CIBER-Consorcio Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (CB21/13/00055 and CB21/13/00099), Ministerio de Ciencia e Innovación and Unión Europea-NextGenerationEU by project IN607D 2024/008 to J.A.-S. (GAIN-Agencia Gallega de Innovación, Consellería de Economía, Emprego e Industria), and "Axudas para a consolidación de grupos de investigación" (IN607A 2024/09 to G.B. and IN607D 2024/08 to J.A.-S.). J.A.-S. was financially supported by the Juan Rodés program (ISCIII, JR21/00026), J.C.V.-U. was financially supported by IN606B-2022/009 (GAIN-Xunta de Galicia). P.G.-S. was financially supported by grant IN606A 2021/021 (Xunta de Galicia). M.O.-G. was financially supported by IN606A 2023/023 (GAIN-Xunta de Galicia). I.A.-G. was financially supported by the Juan Rodés (ISCIII, JR23/00036). G.A.B.-B. was financially supported by IN606A-2024/033. A.R.-C. was financially supported by the FI24/00178 (ISCIII). A.M. was supported by CD23/00057 (ISCIII). L.G.-P. was supported by FI23/00074 (ISCIII). A.G.-P was financially supported by FPU24/02755 (Ministerio de Ciencia, Innovación y Universidades) and IN606A-2025/034 (GAIN-Xunta de Galicia).
dc.identifier.citationRodríguez-Coello A, Outeda-García M, García-Pose A, Gonzalez-Pinto L, Báez-Barroso GA, Guijarro-Sánchez P, Muras A, Taltavull B, Fraile-Ribot P, Alonso-Garcia I, Oliver A, Vázquez-Ucha JC, Arca-Suárez J, Bou G, Beceiro A. In vivo efficacy of cefiderocol against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa carrying the AmpC E219K substitution. Antimicrob Agents Chemother. 2026 Oct 7;70(10):e0072426.
dc.identifier.doi10.1128/aac.00724-26
dc.identifier.issn0066-4804
dc.identifier.urihttps://hdl.handle.net/2183/49822
dc.language.isoeng
dc.publisherAmerican Society for Microbiology
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023/PI23%2F00851/ES/Actividad in vivo de nuevos inhibidores de carbapenemasas frente a patógenos críticos multirresistentes: K. pneumoniae productor de carbapenemasas y P. aeruginosa./
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023/PI24%2F00920/ES/Vacunas versátiles basadas en ARN para combatir las infecciones causadas por cepas multirresistentes de Pseudomonas aeruginosa/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023/PI22%2F01212/ES/Inhibidores de carbapenemasas: actividad frente a Enterobacterales productores de carbapenemasas, mecanismos e impacto en la evolución de la resistencia antimicrobiana (PROTECT)/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica, Técnica y de Innovación 2024-2027/PI25%2F00116/ES/Medicina personalizada frente a Gram negativos prioritarios: posicionamiento de nuevos ß-lactámicos, evolución dirigida del resistoma y diagnóstico de precisión con MALDI-TOF y machine learning/
dc.relation.urihttps://doi.org/10.1128/aac.00724-26
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectE219K
dc.subjectPDC
dc.subjectPseudomonas aeruginosa
dc.subjectCefiderocol
dc.subjectCeftazidime/avibactam;
dc.subjectCeftolozane/tazobactam
dc.subjectMurine infection
dc.titleIn Vivo Efficacy of Cefiderocol against Ceftolozane/Tazobactam- and Ceftazidime/Avibactam-Resistant Pseudomonas Aeruginosa Carrying the AmpC E219K Substitution
dc.typejournal article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublication909e08d1-6ed1-4b99-9e9e-c64eb72e7dea
relation.isAuthorOfPublication.latestForDiscovery909e08d1-6ed1-4b99-9e9e-c64eb72e7dea

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
RCoello_Invivo_2026.pdf
Size:
467.13 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
RCoello_Invivo_2026_Suppl.docx
Size:
129.72 KB
Format:
Microsoft Word XML
Description:
Supplemental material